LOGO
LOGO

Quick Facts

Arbitron And Nielsen Voluntarily Provide FTC Additional Time For Merger Review

By RTTNews Staff Writer   ✉  | Published:  | Google News Follow Us  | Join Us
rttnewslogo20mar2024

The media and marketing research company Arbitron Inc. (ARB) Monday announced that, following informal discussions with the staff at the Federal Trade Commission or "FTC", Arbitron and Consumer information and measurement firm Nielsen Holdings, N.V. (NLSN) have agreed to voluntarily provide the FTC with additional time in which to review the proposed merger of TNC Sub I Corporation, a wholly owned subsidiary of Nielsen, with and into Arbitron.

Arbitron said that Nielsen, as the acquiring party, will withdraw and refile its pre-merger notification and report form under the Hart-Scott-Rodino Antitrust Improvements Act, which will restart the 30-day time frame for initial review of the transaction.

The waiting period for the new filing will expire at 11:59 p.m. on March 8, 2013, unless earlier terminated by the FTC, or the FTC makes a formal request for additional information prior to the expiration of the waiting period.

In December 2012, Nielsen Holdings had announced a definitive agreement to acquire Arbitron for $48 per share in cash. The deal was estimated to be valued at $1.3 billion. The offer price represented a premium of around 26 percent to Arbitron's closing price on December 17.

For comments and feedback contact: editorial@rttnews.com

Business News

Global Economics Weekly Update - Jun 01 - Jun 05, 2026

June 05, 2026 16:18 ET
A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.

Latest Updates on COVID-19